RxDoctor Payments Data

Heather Glover

Family · Bono, ARNPI 1265794564

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 54 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$442
  • GSK$337
  • Axsome Therapeutics, Inc.$139
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
  • AstraZeneca$72
  • Otsuka America Pharmaceutical, Inc.$70
  • plus $154 from 8 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 70th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$108,380
Medicare patients
393
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol52$32,317
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$31,580
OzempicSemaglutide29$24,808
MounjaroTirzepatide18$24,363
EliquisApixaban32$19,311
LinzessLinaclotide17$8,961
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,093
Spiriva RespimatTiotropium Bromide12$6,140
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,947
Dexlansoprazole DrDexlansoprazole11$3,345
Albuterol Sulfate HfaAlbuterol Sulfate78$2,808
Theophylline ErTheophylline Anhydrous12$2,191
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$2,030
Gabapentin63$1,393
Ventolin HfaAlbuterol Sulfate21$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$72$32,31752 claims
GSKTrelegy Ellipta$337$31,58046 claims
Lilly USA, LLCMounjaro$14$24,36318 claims
PfizerEliquis$12$19,31132 claims
AbbVieLinzess$442$8,96117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,103 family providers in Arkansas.

Other family in Bono

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →